All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked, What needs to be considered in patients with MPN with COVID-19?
What needs to be considered in patients with MPN with COVID-19?
To introduce the topic, Barbui discusses a Swedish population-based study that reported that patients with MPN and myelofibrosis were particularly vulnerable to infections. He gives a thorough discussion on the results of an international study evaluating patients with different phenotypes of MPN and COVID-19 conducted by the European LeukemiaNet (ELN). Notably, Barbui believes that patients with MPN with COVID-19 taking ruxolitinib should not discontinue treatment during the acute COVID-19 phase due to its anti-inflammatory properties. Finally, Barbui touches upon the response rate of patients with MPN to COVID-19 vaccines.
Use of ruxolitinib in patients with severe COVID-19
Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor that has a good safety profile and is currently approved for the treatment of myelofibrosis, polycythemia vera, and acute graft-versus-host...
Predictive factors of mortality in patients with hematological malignancies diagnosed with COVID-19
During this COVID-19 pandemic, patients with hematological malignancies—who are immunocompromised because of the cancer itself, immunosuppressive...
Subscribe to get the best content related to MPN delivered to your inbox